Clinical Trials

514 enrolled

Phase 1 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07495098 2026-03-27

Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer

12 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07497607 2026-03-27

REDUCE-30

31 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

33 enrolled

Esophageal Squamous Carcinoma

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

42 enrolled

Uterine Cervical Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2/3 Not yet recruiting

33 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

116 enrolled

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT07452601 2026-03-05

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT07418866 2026-02-18

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07418931 2026-02-18

CECYDE

108 enrolled

Advanced Squamous Non-Small Cell Lung Cancer

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

78 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

50 enrolled

Ovarian Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Other solid neoplasmThoracic

126 enrolled

Mesothelioma, Malignant

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

22 enrolled

Esophageal Squamous Cell Carcinoma

NCT07392580 2026-02-06

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

20 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07393477 2026-02-06

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT07214987 2026-01-30

PDT For Induction Therapy For Head And Neck Cancer

26 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT07369791 2026-01-28

NOBLE

76 enrolled

Advanced Biliary Tract Cancer(BTC)

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Phase 1 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07353294 2026-01-20

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

12 enrolled

Lymphatic Metastasis

NCT07346807 2026-01-16

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

69 enrolled

Tongue Squamous Cell Carcinoma

NCT07349225 2026-01-16

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

46 enrolled

ES-SCLC

NCT06855225 2026-01-14

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

29 enrolled

Liver Neoplasms

NCT07321912 2026-01-08

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

406 enrolled

Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT07244965 2025-11-24

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

42 enrolled

Uterine Cervical Neoplasms

NCT07238569 2025-11-20

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

516 enrolled

Nasopharyngeal Cancinoma (NPC)

NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

165 enrolled

Extensive Stage Lung Small Cell Cancer

NCT07088731 2025-09-22

Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

180 enrolled

Uterine Cervical Neoplasms

NCT07184021 2025-09-19

No Acronym

Genitourinary

Urinary Bladder Neoplasms

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

53 enrolled

Nasopharyngeal Carcinoma

NCT07145931 2025-08-28

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

24 enrolled

Head and Neck Cancer Squamous Cell Carcinoma

NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

10 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT07136519 2025-08-22

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Phase 1 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

12 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasms

NCT07109167 2025-08-07

The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

Biliary Tract Neoplasms

NCT07110558 2025-08-07

PUPA

59 enrolled

Nasopharyngeal Carcinoma

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT07061535 2025-07-11

STAR-SCLC

40 enrolled

Small Cell Lung Carcinoma

NCT07030140 2025-06-22

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07003815 2025-06-04

Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer

62 enrolled

Biliary Tract Neoplasms

NCT06894459 2025-04-30

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

180 enrolled

Phase 4 Not yet recruiting

Head and Neck Neoplasms

NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Small Cell Lung Carcinoma

NCT06861712 2025-04-25

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

50 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

76 enrolled

Phase 4 Not yet recruiting

NSCLC

NCT06931145 2025-04-23

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

50 enrolled

Phase 2/3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06923475 2025-04-11

NEODISCO

150 enrolled

Cholangiocarcinoma, Klatskin Tumor

NCT06903273 2025-03-30

TisGCS for BTC

35 enrolled